Ayelet Nelson, NP
Adult Health · Clifton, NJNPI 1235362120
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Bristol Myers Squibb at 41.9% of the total. Reporting peaked in 2022 at $1,121 and has fallen 86.4% since, to $152 in 2024.
Across 41 payments — averaging $54.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$936
- Incyte Corporation$284
- Takeda Pharmaceuticals U.S.A., Inc.$256
- Janssen Scientific Affairs, LLC$250
- Pfizer$134
- Johnson & Johnson$60
- plus $312 from 12 others
What the payments were for
- Consulting fees$1,18653%
- Food & beverage$74633%
- Education$30013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 2 | $936 |
| Incyte Corporation | 3 | $284 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $256 |
| Janssen Scientific Affairs, LLC | 1 | $250 |
| Pfizer | 9 | $134 |
| Johnson & Johnson | 4 | $60 |
| Merck | 4 | $58 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 2 | $37 |
| Beigene USA, Inc. | 2 | $26 |
| Cumberland Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| CTI Biopharma Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,232 in reported general payments places this provider in the 80th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 23 | $774 |
| Ondansetron OdtOndansetron | 32 | $339 |
| Dexamethasone | 11 | $122 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other adult health in Clifton
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.